The notices it replaced
- Reissues: PAR-16-301 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)
Replaced by PAR-19-330.
Who won it before
18 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,818,607 in first-year total cost, median $626,530.
Most frequent study sections
- Clinical Trials Review Study Section[CLTR (MA)]6
- Clinical Trials Review Study Section[CLTR (JA)]4
- Clinical Trials Review Study Section[CLTR (OA)]4
- Special Emphasis Panel[ZHL1 CSR-H (F2)]2
- Special Emphasis Panel[ZHL1 CSR-H (F1)]1
Most frequent institutions
- RESEARCH TRIANGLE INSTITUTE3
- DUKE UNIVERSITY2
- UNIVERSITY OF UTAH2
- BOSTON CHILDREN'S HOSPITAL1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | 2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)1U24HL147018-01A1 | CASPER, THERON C | UNIVERSITY OF UTAH, UT | $906,728 | ZHL1 |
| 2020 | RACE-CARS DCC 2/21U24HL146938-01A1 | AL-KHALIDI, HUSSEINMARK, DANIEL B | DUKE UNIVERSITY, NC | $697,029 | CLTR |
| 2020 | 2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial1U24HL148563-01A1 | CASPER, THERON C | UNIVERSITY OF UTAH, UT | $659,657 | ZHL1 |
| 2020 | 2/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis1U24HL147012-01A1 | CHEN, YING QINGHUANG, YING | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $508,756 | CLTR |
| 2019 | 2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)1U24HL143217-01A1 | BROOKS, MARIA MORI | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $994,923 | ZHL1 |
| 2019 | 2/2 ICECAP: Influence of Cooling duration on Efficacy in Cardiac Arrest Patients1U24HL145272-01A1 | RAMAKRISHNAN, VISWANATHANYEATTS, SHARON DZIUBA | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $593,402 | CLTR |
| 2019 | Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study1U24HL145265-01A1 | FLAHERTY, KEVIN RSPINO, CATHERINE A | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $582,305 | CLTR |
| 2019 | 2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center1U24HL140090-01A1 | CATELLIER, DIANE J | RESEARCH TRIANGLE INSTITUTE, NC | $527,881 | CLTR |
| 2019 | 2/2: An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study.1U24HL140109-01A1 | PARKER, ROBERT A. | MASSACHUSETTS GENERAL HOSPITAL, MA | $488,203 | CLTR |
| 2019 | 2/1 Arrest Respiratory Failure due to Pneumonia (ARREST PNEUMONIA)1U24HL141727-01A1 | DESAI, MANISHA | STANFORD UNIVERSITY, CA | $377,990 | CLTR |
| 2019 | 2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC1U24HL141732-01A1 | AMBROSIUS, WALTER T | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $221,385 | CLTR |
| 2018 | 2/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE)1U24HL137907-01A1 · under PAR-16-301 | BARNHART, HUIMAN X | DUKE UNIVERSITY, NC | $1,333,276 | CLTR |
| 2018 | Transfusion of Prematurity Early School Age Follow-up (TOP 5) DCC1U24HL143216-01 · under PAR-16-301 | DAS, ABHIK | RESEARCH TRIANGLE INSTITUTE, NC | $1,298,791 | CLTR |
| 2018 | 2/2: A Randomized Controlled Trial of Pravastatin for the Prevention of Preeclampsia in High Risk Women1U24HL140168-01 · under PAR-16-301 | CLIFTON, REBECCA GERSNOVIEZTHOM, ELIZABETH ANN | GEORGE WASHINGTON UNIVERSITY, DC | $1,091,697 | CLTR |
| 2018 | Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea - DCC1U24HL140412-01 · under PAR-16-301 | REDLINE, SUSAN S.WANG, RUI | BRIGHAM AND WOMEN'S HOSPITAL, MA | $896,611 | CLTR |
| 2018 | 2/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (DCC)1U24HL141723-01 · under PAR-16-301 | WYPIJ, DAVID | BOSTON CHILDREN'S HOSPITAL, MA | $812,214 | ZHL1 |
| 2017 | 2/2 Hydrocortisone for BPD Respiratory and Developmental Outcomes Study (HYBRiD Outcomes Study): Data Coordinating Center1U24HL137729-01 · under PAR-16-301 | DAS, ABHIK | RESEARCH TRIANGLE INSTITUTE, NC | $487,278 | CLTR |
| 2017 | 2/2 Catheter-Directed Therapy for Chronic DVT (C-TRACT Trial)-DCC1U24HL137835-01 · under PAR-16-301 | KEARON, CLIVE | MCMASTER UNIVERSITY, ON | $340,481 | CLTR |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.